PERSPECTIVE

Current paradigms and evolving concepts in metastatic castration-resistant prostate cancer

Sumanta Kumar Pal1 and Oliver Sartor2

Until recently, docetaxel-based therapy represented the only therapy shown to prolong survival in patients with metastatic castration-resistant prostate cancer (mCRPC). The past year and a half has been marked by unprecedented progress in treatments for this disease. Three positive phase III clinical trials have emerged, each evaluating agents (sipuleucel-T, cabazitaxel and abiraterone) with distinct mechanisms of action. Herein, the three pivotal trials are described alongside both past and current large phase III studies conducted in this mCRPC. The overall survival for patients with mCRPC treated in current clinical trials is considerably longer than noted in the past. We note that more recent trials with older agents have also shown improved survival and discuss potential non-therapeutic biases that influence this critical measure of outcome. The necessity for utilizing randomized trials when evaluating new therapeutics is emphasized given the changing prognosis in this mCRPC.

Keywords: abiraterone; bevacizumab; cabazitaxel; castrate resistant; castration resistant; docetaxel; hormone refractory; Jevtana; Provenge; prostate cancer; sipuleucel-T

INTRODUCTION

In 2010, an estimated 217,730 cases of prostate cancer were diagnosed in the United States, accounting for 28% of new cancers in men.1 Although these numbers are remarkable, the peak incidence was observed in the earlier half of the last decade when widespread prostate-specific antigen (PSA) screening was introduced for the first time. Annual age-adjusted prostate cancer death rates have declined over the past several years.2 The root causes of these trends are multifold. Adoption of PSA screening has led to a dramatic increase in the incidence of asymptomatic low-risk disease as shown in prospective randomized trials.3–5 The increased use of PSA has led to a drastic stage migration, with only a small proportion of patients now presenting with metastatic disease in the United States.6 Therapies for localized prostate cancer have been refined, not only through novel surgical and radiation-based modalities, but also through additions of adjuvant androgen-deprivation therapy in selected setting.7,8 The collective effects of these therapeutic efforts have likely contributed to the declining rates of prostate cancer-related death.

Until recently, it was challenging to argue that advances in the management of metastatic castration-resistant prostate cancer (mCRPC) were significantly altering survival (Table 1). The first chemotherapy regimen approved for mCRPC, mitoxantrone at 12 mg m\(^{-2}\) with prednisone, was adopted on the basis of palliative benefit in a National Cancer Institute (NCI) Canada trial. This study randomized 161 patients with symptomatic CRPC to mitoxantrone and prednisone or prednisone alone from August 1990 to April 1994.9 The study failed to meet several secondary end points, including overall survival (OS). A subsequent Cancer and Leukemia Group B (CALGB) study produced similar results.10 In CALGB 9182, 242 patients were randomized to either mitoxantrone with hydrocortisone or hydrocortisone alone. Again, mitoxantrone rendered no benefit with respect to OS.

Mitoxantrone and prednisone became a standard of care for mCRPC and comprised the comparator arm in two subsequent pivotal studies evaluating docetaxel.11,12 First, in the TAX 327 trial, a total of 1006 men were randomized March 2000 through June 2002 to receive either docetaxel at one of two schedules or mitoxantrone at 12 mg m\(^{-2}\); all arms contained 10 mg of daily oral prednisone.13 Treatment with docetaxel on a 21-day cycle at 75 mg m\(^{-2}\) was associated with an improvement in median OS (19.2 months vs. 16.3 months, P=0.004). The benefit with docetaxel was noted across various subgroups categorized by age, baseline pain symptoms and baseline PSA. Second, Southwest Oncology Group (SWOG) trial 9916 randomized 674 patients to receive either docetaxel and estramustine or mitoxantrone and prednisone with enrollment between October 1999 and January 2003. As in TAX 327, the results of SWOG 9916 identified a survival advantage associated with docetaxel therapy (17.5 months vs. 15.6 months, P=0.02).14 Progression-free survival was 6.3 months in the docetaxel containing arm as compared to 3.2 months.

It is important to note that the NCI Canada trial of mitoxantrone reported a median OS of 10.8 months. Less than a decade later, the TAX 327 study reported a median survival for mitoxantrone at the same dose and schedule of 16.3 months (Table 1). It is critical to appreciate that the differences in survival for the mitoxantrone-containing arms across time was considerably numerically higher than the differences between the mitoxantrone and docetaxel arms.
in TAX 327. This is likely due to the treatment of less symptomatic patients in the TAX 327 study as compared to the NCI Canada trial and emphasizes that patient selection may be just as important as therapeutic choices in the prognosis of patients with mCRPC.

Within the past year and a half, landmark developments in prostate cancer have added additional insights for patients with mCRPC. A diverse array of new agents has been added to the arsenal of therapies shown to prolong survival for mCRPC, including a novel cytotoxic (cabazitaxel), a dendritic cell vaccine (sipuleucel-T) and a novel androgen synthesis inhibitor (abiraterone). Herein, we provide an overview of these important new agents and discuss them in the context of evolving therapeutic choices in the prognosis of patients with mCRPC.

### Table 1 Pivotal trials in the treatment of metastatic castration-resistant prostate cancer (mCPRC) and associated median survival data

<table>
<thead>
<tr>
<th>Author</th>
<th>Year initiated</th>
<th>Prior docetaxel</th>
<th>Comparison</th>
<th>n</th>
<th>Median survival (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tannock et al. 9, (NCI Canada)</td>
<td>1990</td>
<td>N</td>
<td>Prednisone alone</td>
<td>81</td>
<td>10.8</td>
</tr>
<tr>
<td>Kantoff et al. 10, (CALGB 9182)</td>
<td>1992</td>
<td>N</td>
<td>Mitoxantrone plus prednisone</td>
<td>80</td>
<td>10.8</td>
</tr>
<tr>
<td>Sartor et al. 12 (Cytogen)</td>
<td>1993</td>
<td>N</td>
<td>Hydrocortisone</td>
<td>123</td>
<td>12.6</td>
</tr>
<tr>
<td>Small et al. 13 (CALGB 9583)</td>
<td>1996</td>
<td>N</td>
<td>Mitoxantrone plus hydrocortisone</td>
<td>119</td>
<td>12.3</td>
</tr>
<tr>
<td>Berry et al. 14 (BMS, US Oncology)</td>
<td>1998</td>
<td>N</td>
<td>Placebo</td>
<td>51</td>
<td>7.0</td>
</tr>
<tr>
<td>Petrylak et al. 15 (SWOG 9916)</td>
<td>1999</td>
<td>N</td>
<td>Samarium-153 EDTMP</td>
<td>101</td>
<td>7.0</td>
</tr>
<tr>
<td>Tannock et al. 16 (TAX 327)</td>
<td>2000</td>
<td>N</td>
<td>Anti-androgen withdrawal (AAW)</td>
<td>132</td>
<td>16.7</td>
</tr>
<tr>
<td>Carducci et al. 17 (Abbott)</td>
<td>2001</td>
<td>N</td>
<td>AAW plus ketoconazole</td>
<td>128</td>
<td>15.3</td>
</tr>
<tr>
<td>Sternberg et al. 18 (SPARC)</td>
<td>2003</td>
<td>Y</td>
<td>Docetaxel (q3w) plus prednisone</td>
<td>334</td>
<td>17.4*</td>
</tr>
<tr>
<td>Kantoff et al. 19 (IMPACT)</td>
<td>2003</td>
<td>N</td>
<td>Docetaxel (q1w) plus prednisone</td>
<td>335</td>
<td>17.5*</td>
</tr>
<tr>
<td>Kelly et al. 20 (CALGB 90401)</td>
<td>2005</td>
<td>N</td>
<td>Docetaxel plus prednisone</td>
<td>334</td>
<td>17.4*</td>
</tr>
<tr>
<td>Scher et al. 21 (ASCENT II)</td>
<td>2006</td>
<td>N</td>
<td>Docetaxel plus prednisone and bevacizumab</td>
<td>524</td>
<td>22.6</td>
</tr>
<tr>
<td>de Bono et al. 22 (TROPIC)</td>
<td>2007</td>
<td>Y</td>
<td>Docetaxel plus prednisone</td>
<td>378</td>
<td>15.1*</td>
</tr>
<tr>
<td>de Bono et al. 23 (COU-AA-301)</td>
<td>2008</td>
<td>Y</td>
<td>Docetaxel plus prednisone</td>
<td>378</td>
<td>15.1*</td>
</tr>
</tbody>
</table>

*Overall survival advantage (P<0.05) associated with the respective treatment arm.

**A DENDRITIC CELL VACCINE FOR PROSTATE CANCER: SIPULEUCEL-T**

Sipuleucel-T is an autologous cellular immunotherapy derived from host peripheral blood mononuclear cells activated by a recombinant fusion protein (PA2024) comprised of prostatic acid phosphatase fused to granulocyte-macrophage colony-stimulating factor (GM-CSF). The agent has undergone a complex evolution while on its course for approval in the setting of CRPC. In an early phase III study (D9901), 127 patients with asymptomatic mCRPC were randomized in a 2 : 1 fashion to receive sipuleucel-T or a series of non-activated cells (placebo), respectively.15 Patients were offered a cryopreserved product at the time of disease progression. The primary end point of the study (time to progression, TTP) was not met. However, there was a benefit in OS with sipuleucel-T prolonging survival by 4.5 months compared to placebo (25.9 months vs. 21.4 months, P=0.01). When results of a second similar study (D9902A) that had 98 patients enrolled was combined with the results of D9901, survival benefit observed with sipuleucel-T was preserved (23.2 months vs. 18.9 months, P=0.011).16 Although the OS advantage seen with sipuleucel-T in D9901 and D9902A leads to an initial US FDA filing, the results were criticized in light of the small number of patients on the initial trials and a failure to demonstrate an improvement in the primary study end point, TTP.

Responding to these critiques, the larger D9902B study utilized a similar 2 : 1 randomization of sipuleucel-T to placebo, but employed OS as the primary end point and included a total of 512 patients.18 Eligibility criteria required mCRPC patients that were asymptomatic or minimally symptomatic, an important distinction to note. The study also excluded patients with visceral metastases which have been linked to poor prognosis. The majority of patients enrolled had a low Gleason score (≤7, 75%) and only a small proportion had received prior chemotherapy (19.6%). More than 80% of patients had an Eastern Cooperative Oncology Group performance status of zero. As in D9901 and D9902A, a benefit in OS but not TTP was observed (OS of 25.8 months vs. 21.7 months, P=0.03). Of note the control group lived longer than docetaxel treated patients in the TAX 327 study. On the basis of the D9901, D9902A and D9902B data, sipuleucel-T was granted approval by the US FDA in April 2010.19

The lack of improvement in TTP in all studies of sipuleucel-T therapy may imply that the time to utilization of docetaxel and other subsequent therapies could remain constant, although this requires...
further assessment. Although a median OS of 25.8 months is encouraging, differences in the study population at trial enrollment make it inappropriate to directly compare sipuleucel-T to modalities such as docetaxel. It has long been known that symptoms influence survival and the high percentage of patients with an excellent performance status (Eastern Cooperative Oncology Group performance status of 0) needs to be kept in mind when interpreting longevity. In evaluating immunotherapy, a novel set of response criteria has been proposed based on experience with the CTLA4-directed monoclonal antibody ipilimumab.20 These criteria acknowledge four specific response patterns associated with the agent, including (i) shrinkage in baseline lesions without the occurrence of new lesions; (ii) durable stable disease; (iii) response in new lesions that are incurred; and (iv) response after an increased in overall tumor burden occurs. Utilizing the collective experience of immune-modulating agents to establish novel response criteria may be necessary as these treatments move to the forefront of cancer therapy. It remains to be seen whether such guidelines will be applicable to agents such as sipuleucel-T, however.

Ultimately, it would be prudent to identify biomarkers that may predict response to sipuleucel-T. However, at present, the immune effects of the drug have not been fully characterized. Sheikh et al. recently presented data correlative studies paired with phase III clinical trials of sipuleucel-T.21 At the time of each leukapheresis, a proportion of peripheral blood mononuclear cells were sequestered and stimulated with GM-CSF. In contrast to these cells, sipuleucel-T (i.e., peripheral blood mononuclear cells stimulated with PA2024) had increased antigen-presenting cell activation-associated cytokines (IL-12, IL-10, IL-12 and TNF-α) and T-cell activation-associated cytokines (IL-2, IL-4, IL-5, IL-6, IL-10, IL-13, IFN-γ and TNF-α). The rather broad scope of the PA2024-induced cytokine response makes it challenging to identify a specific marker of activity. Future studies are challenged with defining a panel of moieties that serve such a role.

A NOVEL TAXANE FOR CRPC: CABAZITAXEL
The preclinical activity of cabazitaxel was first reported nearly a decade ago, with low inhibitory concentrations noted across multiple cell lines (IC50 = 3–29 ng ml\(^{-1}\)).22 A subsequent phase I clinical trial enrolled 25 patients with advanced solid tumors, including eight patients (32%) with prostate cancer.23 On the basis of the preclinical and phase I data, a phase III trial (TROPIC) was initiated for patients with mCRPC who progressed despite prior docetaxel therapy.24 Patients were randomized to receive up to 12 cycles of cabazitaxel (25 mg m\(^{-2}\)) with prednisone or mitoxantrone (12 mg m\(^{-2}\)) with prednisone between January 2007 and October 2008. Failure of prior docetaxel was defined for non-measurable disease by the presence of two consecutive PSA rises or appearance of new lesion and for measurable disease by Response Evaluation Criteria in Solid Tumors.

A total of 755 patients were ultimately randomized on the TROPIC study, with a median age of 68 years and a median of seven prior cycles of docetaxel.24 The vast majority of patients had an Eastern Cooperative Oncology Group performance status of 0–1 (92%).20 The trial met its primary end point of OS with an improvement from 12.7 months with mitoxantrone to 15.1 months with cabazitaxel (P<0.0001). In analyses of subgroups, the benefit of cabazitaxel appeared to be relatively consistent. Survival analyses favored cabazitaxel in groups based on baseline pain status, the number of prior cytotoxic agents rendered, age and performance status. These encouraging results have led to the design of a new phase III clinical trial that will compare two doses of cabazitaxel therapy (20 or 25 mg m\(^{-2}\)) to docetaxel at standard doses (75 mg m\(^{-2}\)) as initial chemotherapy for patients with mCRPC.25

With respect to quality of life-driven end points, cabazitaxel did not lead to a significant improvement in the time to pain progression. Notable toxicities associated with cabazitaxel in the TROPIC study include neutropenia—grade ≥3 neutropenia occurred in 82% of patients, with a further 8% of patients developing febrile neutropenia. Importantly, seven patients (2%) receiving cabazitaxel therapy died of neutropenic complications.24 The most common non-hematological toxicities (grade 3 or worse) incurred with cabazitaxel were diarrhea (6%), fatigue (5%) and asthenia (5%). Of note, five patients (1%) died of cardiac causes.

It is important to note that mitoxantrone in the post-docetaxel mCRPC setting had a longer survival than did the initial randomized NCI Canada study in the ‘first-line’ setting (Figure 1a). The reason for this is probably in part due to the earlier use of first-line chemotherapy (a form of lead time bias) and the selection in the TROPIC trial for good performance status patients with good organ function. Given that not all patients with post-docetaxel progression would have qualified for TROPIC, it is important to remember that survival in clinical trial settings always reflects a selected subset of the more general population. The number of patients who would be eligible for second-line chemotherapy post-docetaxel has yet to be accurately ascertained.

TARGETING HORMONAL AXES IN HORMONE-RESISTANT DISEASE: ABIRATERONE
Since the pivotal observations of Huggins in 1941, the role of castration in prostate cancer therapy has been well established.26,27 Over the past several decades, surgical castration has been largely supplanted by pharmacological interventions, including leutenizing hormone releasing peptide analogues such as goserelin or leuprolide, androgen synthesis inhibitors such as bicalutamide or nilutamide, and antiandrogens such as flutamide or cyproterone acetate.28 Both the LHRH agonists and antiandrogens are used as single agents or in combination with other therapies. However, the majority of patients develop resistance to these agents, in part due to the development of drug-resistance mechanisms.28,29

Like other antiandrogen therapies, abiraterone acetonide (abi) is an aromatase synthesis inhibitor that competitively binds to and inhibits CYP17A1—a key enzyme in the biosynthesis of androgens.30 The preclinical activity of cabazitaxel was first reported nearly a decade ago, with low inhibitory concentrations noted across multiple cell lines (IC50 = 3–29 ng ml\(^{-1}\)).22 A subsequent phase I clinical trial
hormone analogs and antiandrogens. In contrast to these agents, abiraterone is an irreversible inhibitor of CYP17, blocking two critical steps in testosterone biosynthesis: conversion of pregnenolone to 17β-pregnenolone, and conversion of 17β-pregnenolone to dihydroepiandrosterone. Subsequent clinical trials of abiraterone established activity in both chemotherapy-naïve and docetaxel pretreated patients.

Encouraging data from these earlier studies prompted phase III efforts exploring abiraterone in mCRPC patients. The phase III COU-AA-301 study was first reported in October 2010 in abstract form,-randomizing 1195 patients with docetaxel-refractory CRPC in a 2:1 fashion to either abiraterone/prednisone or placebo/prednisone. The use of prednisone alone as the control group emphasizes the lack of consensus for what had constituted ‘standard’ of care in the post-docetaxel setting at the time the trial was initiated. The median age of the study population was 69 years, and majority of patients had received one prior cytotoxic agent (72%). The primary end point of the study was OS, and abiraterone led to an improvement in this measure (14.8 months vs. 10.4 months, P<0.0001). With respect to secondary end points, abiraterone also led to an improvement in radiographic progression-free survival (5.6 months vs. 3.6 months, P<0.0001) and PSA response rate (29.1% vs. 5.5%, P<0.0001). Although a Brief Pain Inventory was performed at baseline, no report of pain-related outcomes is available at this time. Therapy with abiraterone was well tolerated, and in fact, the frequency of adverse events among patients receiving placebo exceeded the frequency among patients receiving abiraterone. The most common grade 3 or 4 toxicities associated with abiraterone included fluid retention (2.3%), hypokalemia (3.8%), hypertension (1.3%) and cardiac disorders (4.1%).

Akin to the TROPIC trial evaluating cabazitaxel, the COU-AA-301 results render abiraterone a viable option in the mCRPC beyond docetaxel, further extending the timeline of anticipated survival in CRPC patients. As with cabazitaxel, current efforts may push abiraterone forward in the current treatment paradigm. An ongoing phase III clinical trial randomizing asymptomatic or mildly symptomatic chemotherapy-naive mCRPC patients to either abiraterone/prednisone or prednisone/placebo has recently completed accrual with interim analyses for progression expected in 2011. Additional phase II efforts are exploring abiraterone in the setting of localized disease, either as neo-adjuvant therapy prior to prostatectomy or in combination with definitive radiation therapy. As results from these studies emerge, the utilization of abiraterone therapy is subject to drastic change. It is likely that abiraterone will move ahead of chemotherapeutic regimens in the overall treatment paradigm as evolving data support that concept.

CURRENT AREAS OF RESEARCH IN CRPC THERAPY

Building on docetaxel

The aforementioned pivotal studies of sipuleucel-T, cabazitaxel and abiraterone have all reported positive OS data within the past year. However, these studies represent only a fraction of the phase III evaluations either ongoing or recently completed in mCRPC. Several studies are investigating the combination of docetaxel with a range of therapeutics. The highly anticipated CALGB 90401 trial randomized 1050 chemotherapy-naive mCRPC patients to docetaxel with either bevacizumab or placebo. No significant improvement in OS was observed (22.6 months with bevacizumab vs. 21.5 months with placebo, P=0.18). The survival data were longer than anticipated in both groups (Figure 1b), underscoring the continuing improvement in survival in patients with mCRPC even when similar therapies are used. The control arm of (docetaxel at 75 mg m-2 every 21 days with prednisone) is analogous to experimental arm in the TAX 327 study, the latter reporting an OS of 19.2 months.

Disappointing results were also noted from the ASCENT II study, randomizing 953 men with CRPC to either weekly docetaxel, high-dose calcitriol and dexamethasone, or every 21 day docetaxel at 75 mg m-2 and prednisone, the latter representing the control group. At the time of an interim analysis, more deaths were observed on the experimental arm. Median OS was superior on the control arm (19.9 months vs. 16.8 months, P=0.019), suggesting either the futility of weekly docetaxel or the negative effect of adding calcitriol to a docetaxel-based regimen.

It remains to be seen whether other current efforts to build upon docetaxel will meet with success. The endothelin A antagonist zibotentan showed promising activity in a relatively large randomized phase II study in mCRPC, but a recent press release for a phase III trial comparing single-agent zibotentan to placebo in patients with mCRPC indicated failure to meet the study’s primary end point of OS—tempering enthusiasm for the agent. Nonetheless, phase III trials evaluating the combination of docetaxel and zibotentan have yet to be reported. A phase III SWOG trial of docetaxel with or without atrasentan (another endothelin antagonist) has also completed accrual in 2010. Mirroring the experience with zibotentan, a prior phase III evaluation comparing single-agent atrasentan to placebo failed to improve survival in mCRPC.

Other notable current efforts in this domain include the phase III ‘Mainsail’ study, randomizing patients with chemotherapy-naive CRPC to docetaxel and prednisone with or without lenalidomide. In a phase I/II trial including patients with non-castrate, non-metastatic biochemically relapsed prostate cancer, treatment with lenalidomide led to PSA declines. A phase I study of paclitaxel and lenalidomide conducted in patients with taxane-refractory CRPC also demonstrated moderate activity. A phase III trial of docetaxel and prednisone with or without OGX-011 (a clusterin inhibitor) is now underway. The impetus for the study was a phase II effort exploring the same randomization in patients with mCRPC. With 82 patients accrued, therapy with OGX-011 was associated with a non-statistically significant improvement in progression-free survival (7.3 months vs. 6.1 months), but OS was relatively prolonged (23.8 months vs. 16.9 months). These results have triggered a phase III trial which will be closely watched. A phase III trial with docetaxel/prednisone with or without dasatinib (a Src-directed compound) is also underway. Though little data support the use of dasatinib, this trial is also of considerable interest given the provocative mechanism of action.

Novel vaccine therapies

In contrast to the favorable results from the phase III evaluation of sipuleucel-T, phase III evaluations of GVAX have produced more sobering results. GVAX represents a cellular vaccine derived from PC-3 and LNCaP prostate cancer cell lines modified to secrete GM-CSF. The VITAL-1 study, initiated in 2004, randomized mCRPC patients to receive either GVAX or docetaxel with prednisone. The study was prematurely terminated based on a futility analysis. A total of 626 patients accrued, survival was 20.7 months with GVAX compared to 21.7 months with docetaxel and prednisone (P=0.78). Generating subsets based on survival predicted by the Halabi nomogram, those patients with a predicted survival >18 months appeared to have more substantial benefit from GVAX therapy; however, such subset analyses have generated little interest. A second large assessment of GVAX, the VITAL-2 study, was also prematurely terminated.
A total of 408 patients with mCRPC were randomized to receive either docetaxel with prednisone or docetaxel with GVAX. At the time of preliminary analysis, more deaths were seen on the GVAX-containing arm (67 vs. 47). Ultimately, OS was noted to be prolonged in patients treated with docetaxel and prednisone, but these data have not been reported in mature datasets. Although VITAL-2 has been criticized for the omission of prednisone in the experimental arm, the overall results from clinical evaluations of GVAX have been negative, and it is unclear that it will be developed further in mCRPC.

In contrast to GVAX, encouraging data were reported from a randomized phase II study examining PROSTVAC-VF. The product encompasses three immunomodulators, B7.1, LFA-3 and ICAM-1, as well as two viral vectors encoding transgenes for PSA. In total, 125 patients with minimally symptomatic, chemotherapy-naive mCRPC were randomized 2 : 1 to receive either PROSTVAC-VF with GM-CSF or the control. As with sipuleucel-T, the agent conferred an improvement in OS (25.1 months vs. 16.1 months, \(P = 0.0061\)) without any benefit in progression-free survival. This control group may have had a shorter than expected survival and phase III trials are clearly needed. A phase III trial of PROSTVAC is presently under development, but we note that future trials in mCRPC will be more complicated given the current availability of multiple therapies now shown to prolong survival.

**Novel endocrine therapies**

As the aforementioned studies illustrate, there have been mixed results from phase III evaluations of agents for mCRPC. Importantly, the agents described herein represent only a small fraction of those in the current pipeline. Among those with a promising phase I/II data is MDV3100, a non-steroidal antiandrogen with greater affinity for the androgen receptor than bicalutamide. Preclinical assessment of MDV3100 also suggests inhibition of nuclear translocation of androgen receptors. A phase I/II evaluation of the agent in 140 patients with mCRPC yielded a decrease in PSA ≥ 50% in 78 patients (56%), with a median radiographic TTP of 47 weeks. MDV3100 is currently being compared to placebo in other trials evaluating both chemotherapy-naive and docetaxel-refractory patients with CRPC.

TAK-700 represents yet another novel endocrine therapy for prostate cancer. Like abiraterone, it inhibits CYP17 at low concentrations (IC\(_{50}\) = 28 nmol l\(^{-1}\)). In a phase I/II study assessing TAK-700 (with or without prednisone) in 26 patients with metastatic CRPC, all patients dosed above a certain threshold (≥ 300 mg oral bid) experienced a decline in PSA. In a subset of 15 evaluable patients receiving TAK-700 doses above this threshold, PSA reductions of ≥ 50% and ≥ 90% were seen in 12 (80%) and 4 (27%) patients, respectively. Phase III efforts are now assessing prednisone with either TAK-700 or placebo in men with mCRPC.

**CONCLUSIONS**

Key results for multiple studies in mCRPC are pending, and each dataset has significant implications for the current treatment algorithm of prostate cancer. For instance, if pivotal studies of MDV3100 are positive post-docetaxel, it will be a challenge to ascertain whether the agents should be sequenced before or after abiraterone or cabazitaxel. We know little about how MDV3100 will perform in patients previously treated with abiraterone and this is an important consideration in designing future trials. Likewise, if larger trials of PROSTVAC-VF show benefit in the chemotherapy-naive setting, is there benefit in addition to sipuleucel-T therapy? Figure 2 summarizes several key ongoing questions in mCRPC clinical research. Moving forward, it will be necessary to address the issues of sequences, combinations and cross-resistance in a logical fashion. Randomized trials are essential given the changing natural history of the disease as pointed out above. Disentangling science and corporate interests is likely to be difficult as multiple agendas will be at the table.

Considerable attention has been focused on biomarkers in recent years. As one prominent example of this, PSA characteristics (baseline PSA, PSA doubling time and PSA decline within 3 months of therapy) have been shown to stratify outcomes with docetaxel chemotherapy in the pivotal TAX327 study. Several examples of...
novel biomarkers exist in the current literature, although they all still require clinical validation. For instance, androgen receptor splice variants are highly expressed in CRPC.65 These isoforms lack a ligand binding domain, and may therefore confer resistance to agents such as abiraterone. Another study is examining the role of the TMPRSS2:ERG fusion gene, which modulates expression of ETS family proteins and in turn regulates prostate cancer growth and proliferation, in the context of predicting abiraterone response.66 Multiple putative biomarkers exist beyond these two examples, including circulating tumor cells and others—a comprehensive discussion of this topic is beyond the scope of this brief review. Given multiple calls to ‘personalize’ cancer care, it is imperative that focus be placed on biomarker discovery and validation in the next generation of clinical trials.

These goals notwithstanding, has the prognosis of CRPC improved within the past decade? Although the answer is ‘yes’, the degree of benefit from individual agents is difficult to quantify. What contributions are attributable to better performance status, better supportive care and various lead time biases versus newer therapeutics is difficult to ascertain underscoring the essential nature of randomized trials both now and in the future. Supportive care is sometimes a neglected aspect of clinical trials. Supportive care is often hard to quantitatively assess, but in certain settings has been clearly shown to have a survival benefit.67 Comparative trials are clearly needed for each new agent in development given the wide variations seen in overall survival using historical data.

Both the disease state itself and treatments are simultaneously and rapidly changing. Given the current multiplicity of available therapies, demonstrating a survival benefit in mCRPC for newer agents will increasingly be a challenge. As highlighted earlier in the context of immunotherapy, the oncology may have to look towards new end points in assessing novel therapies, or perhaps turn to old ones. For instance, maintained quality of life is a central goal in the management of prostate cancer, and a demonstrated improvement in this end point led to the approval of mitoxantrone therapy.68–70 At present, it remains unclear whether the recently approved agents yield benefit in this regard—no improvement in pain scores was observed with cabazitaxel therapy, and trends in pain scores have not been published with sipuleucel-T or abiraterone.19,24,37

In the near future, it will be critical to interrogate current methods of prognostication in mCRPC both in the first- and second-line settings. For instance, the Halabi nomogram has been externally validated and used as a prognostic tool in multiple settings.71 However, it is important to recall that this nomogram was developed using a cohort of patients with mCRPC treated on CALGB protocols between 1991 and 2001. None of these patients received contemporary therapeutic regimens and second-line chemotherapy was virtually unheard of at that time. As described herein, even the past 12 months have been marked by notable advances in mCRPC therapy. Given this rapid evolution, re-examination of such prognostic tools is clearly warranted.

COMPETING FINANCIAL INTERESTS
Sumanta Kumar Pal, MD: Honoraria: Glaxo-Smith-Kline, Pfizer, Sanofi-Aventis, Novartis; research support: Amgen; consulting: Novartis, Genentech; Oliver Sartor, MD: research support: Sanofi-Aventis, Johnson & Johnson; consulting: Sanofi-Aventis, Johnson & Johnson, Medication, Oncogenex and Takeda.

ACKNOWLEDGMENTS
Dr Pal’s efforts are supported by the NIH Loan Repayment Plan (LRP), the BCRCR 15IB-0140 (California Breast Cancer Research Program Junior IDEA Award) and NIH K12 2K2CA001727-16A1. The authors would also like to acknowledge the generous support of Nancy and Ira Norris.

34 Danila DC, Morris MJ, de Bono JS, Ryan CJ, Denmeade SR
36 Ryan C, Efstathiou E, Smith M, Taplin M, Bubley G
37 de Bono JS, Logothetis C, Fizazi K, North S, Chu L
33 Attard G, Reid AHM, A’Hern R, Parker C, Oommen NB
41 Kelly WK, Halabi S, Carducci MA, George DJ, Mahoney JF
31 Attard G, Belldegrun AS, de Bono JS. Selective blockade of androgenic steroid
45 NCT00134056: Phase III study of docetaxel and atrasentan versus docetaxel and
48 Keizman D, Zahurak M, Sinibaldi V, Carducci M, Denmeade S. Clinical
74 Berry WR, Hathorn JW, Dakhil SR, Loesch DM, Jackson DV. Stratifications in mCRPC: results from the phase III ASCENT2 trial.
1941; 17: 1188–93.